Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
OBJECTIVE
Iris neovascularization (INV) and anterior chamber angle neovascularization after radiotherapy for uveal melanoma may lead to neovascular glaucoma and enucleation. However, neovascularization of the anterior ocular segment may respond favorably to treatment with panretinal photocoagulation. The purpose of this study was to evaluate the frequency, interval to development, and predisposing factors of anterior ocular segment neovascularization following iodine 125 (I125) brachytherapy for uveal melanoma.


METHODS
Retrospective, interventional, consecutive case series.


METHODS
Sixty-five patients (65 eyes), consecutively treated with I125 brachytherapy for uveal melanoma from 1995 through 2000 and followed up after radiation therapy for 24 months or more.


METHODS
Clinical findings and ultrasonography characteristics as well as treatment parameters were analyzed.


METHODS
The frequency of INV was determined and the interval to development of INV as well as the predisposing factors were analyzed statistically.


RESULTS
In 15 of 65 eyes (23%), INV was detected after I125 brachytherapy at a mean +/- standard deviation of 26.66+/-11.63 months (median, 24 months; range, 9-48 months). Risk factors displaying the stronger correlation with INV were greater maximal tumor height (P<0.01), greater tumor vascularity (P<0.01), and disinsertion of horizontal rectus muscles (P = 0.01).


CONCLUSIONS
After I125 brachytherapy for choroidal melanoma, INV developed in 23% of eyes and was correlated with larger tumor size, greater tumor vascularity, and disinsertion of a horizontal rectus muscle.
Detorakis
Efstathios T
ET
Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. detorakis@hotmail.com
Engstrom
Robert E
RE
Wallace
Robert
R
Straatsma
Bradley R
BR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000098:blood supply*; D001918:Brachytherapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects*; D007498:Iris / Q000098:blood supply*; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000209:etiology*; D011832:Radiation Injuries / Q000209:etiology*; D012189:Retrospective Studies; D014604:Uveal Neoplasms / Q000532:radiotherapy*
D007457:Iodine Radioisotopes